Get started
MetaVia Inc.MM

MetaVia Inc.

1.59USDR
+0.11+7.44%
Last update at 20:25 GMT
USD
No tradesPost-market
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

MTVA fundamentals

Key facts

Market capitalization‪13.70 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−4.77USD
Founded2014
Employees (FY)8
CEOHyung-Heon Kim
Websiteneurobopharma.com
About

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Ownership
‪‪8.62 M‬‬
Closely held shares
‪‪5.49 M‬‬ (63.72%)
Free Float shares
‪‪3.13 M‬‬ (36.28%)
Closely held shares
‪‪5.49 M‬‬ (63.72%)
Free Float shares
‪‪3.13 M‬‬ (36.28%)
Capital structure
Market cap
‪‪13.70 M‬‬
Debt
‪‪154.00 K‬‬
Cash & equivalents
‪‪21.67 M‬‬
Enterprise value
‪‪−7.81 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪13.70 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24

Growth and Profitability

Company’s recent performance and margins

Performance
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−10.40 M‬‬
‪‪−7.80 M‬‬
‪‪−5.20 M‬‬
‪‪−2.60 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−6.40 M‬‬
‪‪−4.80 M‬‬
‪‪−3.20 M‬‬
‪‪−1.60 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−6.00 M‬‬
‪‪−4.50 M‬‬
‪‪−3.00 M‬‬
‪‪−1.50 M‬‬
‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
Actual
Estimate
Earnings
Next:Mar 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−2.00‬
‪−1.50‬
‪−1.00‬
‪−0.50‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

MTVA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−10.00 M‬‬
‪0.00‬
‪‪10.00 M‬‬
‪‪20.00 M‬‬
‪‪30.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬
Assets
Liabilities